title: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
abstract: OBJECTIVE
  Luteinizing hormone (LH) plays an important role in the development of ovarian cancer, and has been shown to inhibit apoptosis in ovarian cancer cells. Similarly, survivin is a molecule that has been shown to inhibit apoptosis in other types of cancer. Therefore, the aim of this study was to determine whether survivin can be induced by LH in ovarian cancer, and whether this induction influences the sensitivity of ovarian cancers to chemotherapy.
  
  
  METHODS
  Survivin expression was monitored using western blot assays, and flow cytometry was used to detect the effects of cisplatin on the induction of apoptosis by LH. MTT assays were also used to analyze rates of cell proliferation.
  
  
  RESULTS
  Administration of LH in vitro induced survivin expression in a dose-dependent manner. Moreover, this signaling was dependent on the ERK1/2 signaling pathway. LH also blocked apoptosis induced by cisplatin.
  
  
  CONCLUSIONS
  These results suggest that LH influences the sensitivity of ovarian cancer cells to chemotherapy via signaling to inhibit apoptosis that also upregulates survivin.
authors.affiliation: Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, China.
authors.forename: Zhenbo
authors.initials: Z
authors.lastname: Zhang
authors.forename: Hong
authors.initials: H
authors.lastname: Liao
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Chen
authors.forename: Yu
authors.initials: Y
authors.lastname: Zheng
authors.forename: Yingtao
authors.initials: Y
authors.lastname: Liu
authors.forename: Xiang
authors.initials: X
authors.lastname: Tao
authors.forename: Chao
authors.initials: C
authors.lastname: Gu
authors.forename: Lingling
authors.initials: L
authors.lastname: Dong
authors.forename: Tao
authors.initials: T
authors.lastname: Duan
authors.forename: Yixia
authors.initials: Y
authors.lastname: Yang
authors.forename: Xuelian
authors.initials: X
authors.lastname: Liu
authors.forename: Yinhua
authors.initials: Y
authors.lastname: Yu
authors.forename: Youji
authors.initials: Y
authors.lastname: Feng
mesh_terms: D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D002945:Cisplatin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000502:physiology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000378:metabolism*; D009994:Osmolar Concentration; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D000077022:Survivin; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D000077022:Survivin; D007986:Luteinizing Hormone; D002945:Cisplatin